NAMSA

Fifth Annual MedExecWomen Conference in April to Discuss This Year’s Top Opportunities in Medtech

Retrieved on: 
Thursday, March 7, 2024

McEvoy will share eye-opening insights from nearly three decades of experience creating transformational change in healthcare.

Key Points: 
  • McEvoy will share eye-opening insights from nearly three decades of experience creating transformational change in healthcare.
  • The one-day conference also features an agenda of workshops and panels and speakers that span some of this year’s top challenges and opportunities related to medtech innovation, including:
    What do Leading Physicians Think are the Most Innovative Trends in Medtech?
  • “Women in life sciences don’t often get mentors, education, and a network,” said Maria Shepherd , co-founder of MedExecWomen and president of Medi-Vantage.
  • “This conference and community establish this network and bring together a powerhouse group of women in medtech for a truly unique opportunity to connect with one another and discuss some of the most pressing changes and opportunities in medtech each year.”
    Save your spot for this must-attend event for women in medtech — register online today.

Technology Holdings Launches TH Healthcare & Life Sciences: Revolutionizing the Healthcare Investment Banking Landscape, leveraging over two decades of Healthcare Investment Banking transaction experience

Retrieved on: 
Tuesday, February 27, 2024

Technology Holdings , a global investment bank with offices in North America, Europe and the Asia-Pacific, proudly announces the launch of TH Healthcare & Life Sciences , its specialist healthcare investment banking division.

Key Points: 
  • Technology Holdings , a global investment bank with offices in North America, Europe and the Asia-Pacific, proudly announces the launch of TH Healthcare & Life Sciences , its specialist healthcare investment banking division.
  • TH Healthcare & Life Sciences will leverage Technology Holdings 23 years of healthcare transaction expertise, global reach with a presence in 9 countries and deep healthcare and life sciences sector knowledge.
  • TH Healthcare & Life Sciences leverages decades of relationships with key healthcare strategic buyers and private equity funds with a specialized, dedicated team of healthcare investment bankers allowing TH Healthcare & Life Sciences to strategically position healthcare and life sciences businesses and continue to achieve outstanding results for its clients.
  • “We are excited to announce the launch of TH Healthcare & Life Sciences, serviced by a dedicated team of healthcare investment bankers globally across 9 countries and 5 continents.

Nanowear Announces FDA 510(k) Clearance for AI-enabled Continuous Blood Pressure Monitoring and Hypertension Diagnostic Management: SimpleSense-BP

Retrieved on: 
Thursday, January 4, 2024

As the first non-invasive, cuffless, continuous blood pressure monitor, and diagnostic, SimpleSense-BP provides a transformational tool in clinical diagnostic management of hypertension and is additive to the wearable platform’s previously cleared cardiopulmonary diagnostics.

Key Points: 
  • As the first non-invasive, cuffless, continuous blood pressure monitor, and diagnostic, SimpleSense-BP provides a transformational tool in clinical diagnostic management of hypertension and is additive to the wearable platform’s previously cleared cardiopulmonary diagnostics.
  • “This FDA clearance represents an exciting and differentiating moment for Nanowear.
  • SimpleSense-BP is validated to track changes of > +/- 15mmHg systolic and +/- 10mmHg diastolic blood pressures over a continuous recording period across all classes of hypertension, via its wearable undergarment and AI platform.
  • “We often talk about whitecoat syndrome limiting our ability to understand the effect of therapeutics in blood pressure or other cardiopulmonary assessments.

MedTech Innovator Names StrokeDx as 2023 Global Competition Winner at The MedTech Conference

Retrieved on: 
Wednesday, October 11, 2023

MedTech Innovator , the world’s largest accelerator of medical technology companies, today announced that StrokeDx is the winner of its 2023 Global Competition.

Key Points: 
  • MedTech Innovator , the world’s largest accelerator of medical technology companies, today announced that StrokeDx is the winner of its 2023 Global Competition.
  • From among five finalists in the 2023 cohort, the winner was determined by a live audience vote during The MedTech Conference , powered by AdvaMed, on October 10.
  • Two hundred companies were invited to pitch during the MedTech Innovator Road Tour, with 61 companies ultimately participating in the 2023 Cohort.
  • “The MedTech Innovator program has been incredible, and its impact on our company for years to come will be significant,” said Alexander Ballatori, co-founder and CEO, StrokeDx.

Aethlon Medical Announces Fiscal First Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 10, 2023

SAN DIEGO, Aug. 10, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today reported financial results for its fiscal first quarter ended June 30, 2023 and provided an update on recent developments. 

Key Points: 
  • ET
    SAN DIEGO, Aug. 10, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today reported financial results for its fiscal first quarter ended June 30, 2023 and provided an update on recent developments.
  • Aethlon Medical believes that the data generated from this trial will help inform the design of future oncology efficacy trials of the company's Hemopurifier.
  • Financial Results for the First Quarter Ended June 30, 2023
    As of June 30, 2023, Aethlon Medical had a cash balance of approximately $12.9 million.
  • ET to review its financial results for its first quarter ended June 30, 2023 and recent corporate developments.

Technology Holdings Advises SUAZIO, a Data-Driven Life Sciences and MedTech Strategic Consultancy, on Its Sale to NAMSA

Retrieved on: 
Tuesday, April 4, 2023

Founded in 2001 and headquartered in Antwerp, Belgium, with a presence in key European, North American and APAC markets, SUAZIO provides highly specialized data-driven market research, insights, analytics, and consulting services in Life Sciences and MedTech markets.

Key Points: 
  • Founded in 2001 and headquartered in Antwerp, Belgium, with a presence in key European, North American and APAC markets, SUAZIO provides highly specialized data-driven market research, insights, analytics, and consulting services in Life Sciences and MedTech markets.
  • SUAZIO has developed a research-based, end-to-end ecosystem of complementary consulting services and methodologies in 5 domains: Customer insights, Product value drivers, Patient journey, Digital healthcare & Economic value proposition.
  • With the acquisition of SUAZIO, NAMSA deepens its research and product development capabilities and increases its global presence to 20 locations across the Americas, Asia and Europe.
  • Dr Christophe Berthoux, CEO of NAMSA said, “NAMSA is very enthusiastic about expanding its global strategic consulting services with the addition of SUAZIO.

Renowned Hemostat Innovator Joins Medcura to Drive Clinical Studies, Regulatory Pursuits

Retrieved on: 
Tuesday, February 21, 2023

RIVERDALE, Md., Feb. 21, 2023 /PRNewswire/ -- Medcura, Inc. welcomes Rachel Hoffman as its new Senior Vice President of Clinical and Regulatory Affairs. With over 15 years of experience, working on dozens of hemostatic devices across the full spectrum of development, Hoffman embodies powerful leadership to drive the company's technologies forward through clinical studies and regulatory applications. Her role began in January 2023.

Key Points: 
  • RIVERDALE, Md., Feb. 21, 2023 /PRNewswire/ -- Medcura, Inc. welcomes Rachel Hoffman as its new Senior Vice President of Clinical and Regulatory Affairs.
  • With over 15 years of experience, working on dozens of hemostatic devices across the full spectrum of development, Hoffman embodies powerful leadership to drive the company's technologies forward through clinical studies and regulatory applications.
  • Prior to joining Medcura, Hoffman was the Vice President of Clinical Development and Global Head of Medical Device & Diagnostics at Syneos Health, one of the largest global Clinical Research Organizations (CRO).
  • During her tenure there, she expanded the medical device practice from clinical operations to the full spectrum of development, including scientific consulting and regulatory affairs.

Aethlon Medical Announces Third Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Monday, February 13, 2023

SAN DIEGO, Feb. 13, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today reported financial results for its third quarter ended December 31, 2022 and provided an update on recent developments.

Key Points: 
  • SAN DIEGO, Feb. 13, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today reported financial results for its third quarter ended December 31, 2022 and provided an update on recent developments.
  • Financial Results for the Third Quarter Ended December 31, 2022
    As of December 31, 2022, Aethlon Medical had a cash balance of approximately $17.5 million.
  • The Company will hold a conference call today, Monday, February 13, 2022, at 4:30 p.m. EST to review financial results and recent corporate developments.
  • Interested parties without internet access or unable to pre-register may dial in by calling:
    All callers should ask for the Aethlon Medical, Inc. conference call.

Aethlon Medical Announces Contract with NAMSA to Advance Hemopurifier Clinical Programs in Cancer

Retrieved on: 
Monday, January 30, 2023

Pursuant to the agreement, NAMSA will manage Aethlon's study of the Hemopurifier for patients in the United States and Australia with various types of cancer tumors.

Key Points: 
  • Pursuant to the agreement, NAMSA will manage Aethlon's study of the Hemopurifier for patients in the United States and Australia with various types of cancer tumors.
  • "Aethlon is committed to progressing the clinical development of the Hemopurifier," said Charles J. Fisher, M.D., Chief Executive Officer of Aethlon Medical.
  • Aethlon plans to move quickly to leverage this experience to advance our trials with the Hemopurifier in cancer patients."
  • "We are extremely pleased that Aethlon selected NAMSA as their strategic outsourcing partner for their clinical research program," stated Dr. Christophe Berthoux, NAMSA CEO.

InspireMD Reports Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 8, 2022

TEL AVIV, Israel, Nov. 08, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for treatment of carotid artery disease (CAD) and prevention of stroke today announced financial and operating results for the third quarter ended September 30, 2022.

Key Points: 
  • Financial Results for the Third Quarter ended September 30, 2022
    For the third quarter of 2022, total revenue increased 33.6%, to $1,431,000, from $1,071,000 during the third quarter of 2021.
  • Gross profit for the third quarter of 2022 increased by $274,000, or 297.8%, to $366,000, compared to a gross profit of $92,000 for the third quarter of 2021.
  • Total operating expenses for the third quarter of 2022, were $4,976,000, an increase of $853,000, or 20.7% compared to $4,123,000 for the third quarter of 2021.
  • Management will host a conference call at 8:30AM ET today, November 8th, to review financial results and provide an update on corporate developments.